About N-alpha-acetyltransferase 30
N-alpha-acetyltransferase 30 (NAA30) is a protein
from Homo sapiens identified by UniProt accession
Q147X3, 362 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | N-alpha-acetyltransferase 30 |
|---|
| UniProt accession | Q147X3 |
|---|
| Gene | NAA30 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 362 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- basophil count · score 0.33
- basophil percentage of leukocytes · score 0.28
- adolescent idiopathic scoliosis · score 0.15
- lymphocyte count · score 0.07
- glioblastoma multiforme · score 0.03
- neoplasm · score 0.03
- lung adenocarcinoma · score 0.03
- glioblastoma · score 0.01
- Global developmental delay · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q147X3-F1 | alphafold | PREDICTED | 63.23 | — |
Amino-acid sequence (362 residues)
MAEVPPGPSS LLPPPAPPAP AAVEPRCPFP AGAALACCSE DEEDDEEHEG GGSRSPAGGE SATVAAKGHP CLRCPQPPQE QQQLNGLISP ELRHLRAAAS LKSKVLSVAE VAATTATPDG GPRATATKGA GVHSGERPPH SLSSNARTAV PSPVEAAAAS DPAAARNGLA EGTEQEEEEE DEQVRLLSSS LTADCSLRSP SGREVEPGED RTIRYVRYES ELQMPDIMRL ITKDLSEPYS IYTYRYFIHN WPQLCFLAMV GEECVGAIVC KLDMHKKMFR RGYIAMLAVD SKYRRNGIGT NLVKKAIYAM VEGDCDEVVL ETEITNKSAL KLYENLGFVR DKRLFRYYLN GVDALRLKLW LR
Explore N-alpha-acetyltransferase 30 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets